Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History

Amit Sud, Hauke Thomsen, Kristina Sundquist, Richard S. Houlston, and Kari Hemminki

ABSTRACT

Purpose

Although advances in Hodgkin lymphoma (HL) treatment have led to improved disease-free survival, this has been accompanied by an increased risk of second cancers. We sought to quantify the second cancer risks and to investigate the impact of family history.

Patients and Methods

Using the Swedish Family-Cancer Project Database, we identified 9,522 individuals with primary HL diagnosed between 1965 and 2012. We calculated standardized incidence ratios and cumulative incidence of second cancer in HL survivors and compared the standardized incidence ratios of lung, breast, colorectal, and all second cancers in HL survivors with and without a site-specific family history of cancer. Interactions between family history of cancer and HL treatment were evaluated under additive and multiplicative models.

Results

Overall, the risk of a second cancer in HL survivors was increased 2.39-fold (95% CI, 2.29 to 2.53). The 30-year cumulative incidence of breast cancer in women diagnosed with HL at younger than 35 years of age was 13.8%. We observed no significant difference in cancer risk over successive time periods. The risk of all second cancers was 1.3-fold higher for HL survivors with a first-degree relative with cancer \((P = .001)\), with 3.3-fold, 2.1-fold, and 1.8-fold differences shown for lung, colorectal, and breast cancers, respectively. Moreover, a greater than additive interaction between family history of lung cancer and HL treatment was shown \((P = .03)\).

Conclusion

HL survivorship is associated with a substantive risk of a second cancer. Notably, the risk is higher in individuals with a family history of cancer. This information should be used to inform risk-adapted therapy and to assist in screening to reduce long-term morbidity and mortality in patients with HL.

J Clin Oncol 35:1584-1590. © 2017 by American Society of Clinical Oncology. Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
with a prior history of cancer other than HL, which potentially biased the conclusions.

To gain insight into the risk of second cancer after a diagnosis of HL and its relationship to temporal changes in treatment regimens, we analyzed data on a cohort of 9,522 Swedish patients. In addition, through the use of the Swedish Family-Cancer Project Database, we performed an updated analysis of the influence of family history, as a surrogate for genetic susceptibility, on the risk of second cancer in patients with HL.

**Patients and Methods**

**Patients**

The Swedish Family-Cancer Project Database was created by linking information from the multigeneration register, national censuses, the Swedish Cancer Registry, and death notifications. The Swedish Cancer Registry, established in 1958, is based on the compulsory reporting of all diagnosed patients, thereby providing near-complete coverage of all cancer registrations in Sweden. There is an under-representation of individuals in the first generation in some families; however, this has not been shown to adversely bias estimates of familial risk. In this study, we analyzed all incident cases of HL between 1965 and 2012. Individuals with a diagnosis of malignancy before HL were excluded. Individuals with HL were observed until December 31, 2012, time of migration from Sweden, or death. Data regarding HL histologic subtype were available for all individuals diagnosed since 1993. The database includes the date and site of occurrence of up to four subsequent new malignancies after diagnosis of HL and dates and causes of death. Cancers in the first year after HL diagnosis were omitted from our analysis because of the likelihood of excess cases as a result of increased surveillance. First-degree relatives (FDRs) of individuals with HL, as well as the dates and sites of cancer diagnoses in the FDRs, were identified. The study was undertaken with approval from the ethics committee at Lund University, Sweden, and was conducted in accordance with the tenets of the Declaration of Helsinki.

**Statistical Analysis**

Expected numbers of cancers were computed using 5-year age, sex, and calendar period incidence rates for Sweden. Observed numbers were compared with expected numbers by means of the standardized incidence ratio (SIR) assuming a Poisson distribution. The risk of a second malignancy was estimated for different time intervals after treatment of HL. The absolute excess risk (AER) was calculated as the observed number of second cancers in our cohort minus that expected, divided by the number of person-years at risk, multiplied by 10,000. SIRs were calculated in the HL cohort and were stratified by patient characteristics. Tests for trend in SIRs were performed by evaluating the likelihood function in collapsed person-time additive Poisson regression models with and without the inclusion of the variable. Patients in whom multiple second cancers were diagnosed were counted only once in the analysis of all second cancers; in this analysis, the time at risk ended on the date on which a second cancer was diagnosed. For the site-specific cancer analyses, the time at risk ended on the date on which the site-specific cancer was diagnosed, regardless of whether this was preceded by another cancer. The cumulative incidence of second cancer was estimated with death treated as a competing risk. Interaction contrast ratios (ICRs) and multiplicative interaction indexes (MIIs) were used to investigate the possible interaction between HL treatment and family history of cancer.

**RESULTS**

**Patients and Record Linkage**

From the Swedish Family-Cancer Project Database, data on 9,522 patients with a primary diagnosis of HL between 1965 and 2012 were analyzed. Of the 9,522 patients 5,488 were male and 4,034 were female, with a mean age at diagnosis of 49 years (Table 1). Five thousand seven hundred twenty-one were deceased and 129 had emigrated before the end of the study period. The median follow-up was 12.6 years, with the longest being 48 years. Of patients with HL in whom tumor with histology had been recorded, 1,839 (54%) were nodular sclerosis HL (NSHL) and 539 (16%) were of mixed cellularity HL. Among the 3,917 individuals who died > 1 year after the diagnosis of HL, 842 (9%) died with the occurrence of a subsequent cancer during the follow-up.

**Risk of Second Cancer in Patients With HL**

A total of 1,215 second cancers were observed in 1,121 patients (12% of patients with HL). The risk of all second cancers was elevated significantly after HL diagnosis, with a SIR of 2.39 (95% CI, 2.25 to 2.53), translating to an AER of 71.2 cases per 10,000 person-years (Table 2). In the nonstratified analysis, non-Hodgkin lymphoma (NHL) contributed the most to the AER (16.2% of the excess cancer risk), followed by lung cancer (14.5% of the excess cancer risk), breast cancer (12.9% of the excess cancer risk),...
| Cancer Site | 1-9 | 10-19 | 20-30 | > 30 | > 1 | AER  |
|------------|-----|-------|-------|------|-----|------|
| Cancer overall | 580 | 2.12 (1.96 to 2.30)* | 313 | 2.92 (2.61 to 3.26)* | 165 | 2.55 (2.19 to 2.98)* | 63 | 2.65 (2.07 to 3.39)* | 1121 | 2.39 (2.25 to 2.53)* | 71.2 |
| Pharynx | 7 | 4.25 (2.03 to 8.92)* | 3 | 3.79 (1.22 to 11.74)† | 1 | 2.01 (0.28 to 14.23) | 1 | 2.11 (0.68 to 4.42) | 2 | 3.06 (0.77 to 12.24) | 1.4 |
| Esophagus | 2 | 0.72 (0.18 to 2.90) | 5 | 4.33 (1.80 to 10.41)* | 2 | 2.71 (0.68 to 10.83) | 4 | 12.84 (4.82 to 34.2)* | 13 | 2.62 (1.52 to 4.51)* | 0.8 |
| Stomach | 18 | 1.58 (0.99 to 2.50) | 9 | 2.53 (1.31 to 4.85)† | 1 | 1.11 (0.28 to 4.42) | 2 | 3.06 (0.77 to 12.24) | 31 | 1.78 (1.25 to 2.52)* | 1.4 |
| Colon | 43 | 2.00 (1.49 to 2.70)* | 24 | 2.80 (1.87 to 4.17)* | 12 | 2.26 (1.28 to 3.96)† | 4 | 1.82 (0.68 to 4.86) | 85 | 2.21 (1.78 to 2.74)* | 4.7 |
| Rectum | 19 | 1.47 (0.94 to 2.30) | 7 | 1.29 (0.61 to 2.70) | 4 | 1.17 (0.44 to 3.12) | 2 | 1.41 (0.35 to 5.64) | 32 | 1.38 (0.97 to 1.96) | 0.9 |
| Colon rectum | 60 | 1.75 (1.36 to 2.35)* | 30 | 2.16 (1.51 to 3.09)* | 16 | 1.95 (1.13 to 3.02)* | 6 | 1.68 (0.76 to 3.75) | 112 | 1.85 (1.54 to 2.23)* | 5.4 |
| Hepatobiliary | 11 | 1.48 (0.82 to 2.68) | 3 | 1.09 (0.35 to 3.37) | 3 | 2.00 (0.65 to 6.20) | 1 | 1.80 (0.25 to 12.77) | 18 | 1.47 (0.93 to 2.34) | 0.6 |
| Pancreas | 11 | 1.37 (0.76 to 2.47) | 11 | 3.68 (2.04 to 6.64)* | 5 | 2.96 (1.23 to 7.12)† | 1 | 1.51 (0.21 to 10.69) | 28 | 2.09 (1.44 to 3.03)* | 1.5 |
| Lung | 56 | 2.65 (2.04 to 3.44)* | 40 | 4.48 (3.28 to 6.10) | 31 | 5.41 (3.80 to 7.69)* | 11 | 4.52 (2.50 to 8.16)* | 138 | 3.61 (2.85 to 4.36)* | 10.3 |
| Breast | 39 | 1.27 (0.93 to 1.74) | 64 | 4.16 (3.25 to 5.31)* | 24 | 3.92 (2.80 to 5.48)* | 9 | 3.01 (1.57 to 5.78)* | 146 | 2.52 (2.15 to 2.97) | 9.2 |
| Uterine | 9 | 1.48 (0.77 to 2.84) | 3 | 2.74 (0.35 to 3.40) | 1 | 0.55 (0.08 to 3.90) | 1 | 1.77 (0.18 to 9.00) | 14 | 1.22 (0.73 to 2.07) | 0.3 |
| Prostate | 59 | 1.20 (0.93 to 1.55) | 28 | 1.32 (0.91 to 1.91) | 15 | 0.96 (0.57 to 1.57) | 11 | 1.51 (0.84 to 2.73) | 113 | 1.21 (1.01 to 1.48)* | 2.1 |
| Kidney | 10 | 1.09 (0.58 to 2.02) | 8 | 2.24 (1.13 to 4.50)† | 3 | 1.48 (0.48 to 4.60) | 2 | 2.61 (0.65 to 10.43) | 23 | 1.48 (0.98 to 2.22) | 0.8 |
| Bladder | 21 | 1.54 (1.00 to 2.62) | 8 | 1.36 (0.68 to 2.72) | 9 | 2.44 (1.26 to 4.86)† | 1 | 0.65 (0.09 to 4.61) | 39 | 1.57 (1.15 to 2.15)† | 1.5 |
| Melanoma | 25 | 2.34 (1.58 to 3.46)* | 9 | 1.69 (0.88 to 3.25) | 6 | 2.00 (0.90 to 4.44) | 2 | 1.78 (0.44 to 7.10) | 42 | 2.08 (1.54 to 2.82)* | 2.3 |
| SCC (skin) | 59 | 4.91 (3.80 to 6.35)* | 25 | 4.66 (3.15 to 6.89)* | 11 | 3.52 (1.73 to 5.64)* | 5 | 3.13 (1.30 to 7.52)† | 100 | 4.44 (3.65 to 5.41)* | 8.1 |
| Brain | 15 | 2.06 (1.24 to 3.42) | 9 | 3.06 (1.59 to 5.89)* | 5 | 3.29 (1.37 to 7.91)† | 3 | 4.60 (1.48 to 14.27)† | 32 | 2.58 (1.83 to 3.65)* | 2.1 |
| Thyroid | 10 | 4.18 (2.26 to 7.76)* | 8 | 8.38 (4.20 to 16.77)† | 2 | 4.71 (1.17 to 18.83)† | 3 | 11.43 (2.85 to 45.72)† | 20 | 5.13 (3.31 to 7.94)* | 1.8 |
| Connective tissue | 7 | 3.50 (1.67 to 7.35)† | 7 | 8.20 (3.91 to 17.21)† | 4 | 8.67 (3.25 to 23.06)† | 2 | 11.43 (2.85 to 45.72)† | 20 | 5.73 (3.70 to 8.89)* | 1.7 |
| NHL | 68 | 8.03 (6.33 to 10.18)† | 33 | 8.32 (5.88 to 11.79)* | 21 | 9.08 (5.92 to 13.92)* | 3 | 3.38 (1.09 to 10.46)† | 125 | 7.99 (6.70 to 9.53)* | 11.5 |
| Leukemia | 60 | 8.54 (6.63 to 11.00)* | 10 | 3.51 (1.89 to 6.52)* | 8 | 4.77 (2.39 to 9.54)† | 1 | 1.51 (0.21 to 10.68) | 79 | 6.46 (5.19 to 8.06)* | 6.9 |

Abbreviations: AER, absolute excess risk (No./10,000 person-years); NHL, non-Hodgkin lymphoma; SCC, squamous cell carcinoma; SIR, standardized incidence ratio.

* P < .001.
† P < .05.
‡ P < .01.
Influence of Sex, Age, and Tumor Subtype on Second Cancer Risk

For men diagnosed with HL before the age of 35 years, the SIRs for all second cancers, colorectal cancer, lung cancer, NHL, and leukemia were higher when compared with those diagnosed with HL after the age of 35 years. Similarly, for women diagnosed with HL before the age of 35 years, the SIRs for all second cancers, breast cancer, lung cancer, and NHL were higher when compared with women diagnosed with HL after the age of 35 years (Table 3). In women diagnosed with HL at younger than 35 years of age, the 30-year cumulative risk of breast cancer was 13.8% (95% CI, 11.1 to 16.9), which accounted for > 50% of the AER in this age group of women. This contrasted with women diagnosed with HL at older than 35 years of age for whom the 30-year cumulative incidence of breast cancer was only 3.3% (95% CI, 2.2 to 3.9), and accounted for < 3% of the AER (Fig 1 and Data Supplement). Given the difference in cause and tumor biology of HL histologic subtypes, we investigated whether second cancer risk might also differ. We observed similar SIRs for cancer overall and the common site-specific cancers for the most common subtype, NSHL (Data Supplement). We do acknowledge, however, that this observation should be interpreted with caution because numbers are small and the unclassified HL cases include a proportion of NSHL.

### Temporal Effects on Risk of Second Cancer

Although details of individual patient therapy are not registered by the Swedish Cancer Registry, the treatment principles for HL in Sweden are broadly similar to those of other Western countries. Briefly, extended field irradiation, mainly mantle field, was the standard treatment of patients with HL during the early phase of our analysis. Patients received radiotherapy, chemotherapy, or a combined modality treatment. For those patients treated after 1990, less toxic regimens were being introduced. Partitioning data, we analyzed the second cancer risk for patients diagnosed with HL in the time periods of 1965 to 1977, 1978 to 1988, and 1989 to 2000. We found little evidence of a change in SIRs for overall cancer and for the most common sites of cancer, including hematopoietic malignancy (Data Supplement).

### Impact of Family History on Risk of Second Cancer and Survival

From the Multigenerational Register, a total of 28,277 FDRs of the 9,522 patients with HL were identified. The SIR for cancer risk in FDRs was 1.02 (95% CI, 0.99 to 1.06). In the HL survivors, 2,785 individuals (29%) had one or more FDRs with a family history of cancer (Data Supplement). We found an increase in second cancer risk in HL survivors who had an FDR with cancer, when compared with HL survivors with no FDR with cancer ($P < .001$) with SIRs of 2.83 (95% CI, 2.58 to 3.10) and 2.16 (95% CI, 2.00 to 2.33), respectively. Moreover, the increased risk of second cancer was correlated with the number of FDRs affected with cancer, respective SIRs being 2.67 (95% CI, 2.40 to 2.97) and 3.40 (95% CI, 2.85 to 4.09) for patients with one and two or more affected FDRs ($P < .001$; Data Supplement).

| Cancer Site          | Sex | Age Group | No. | SIR (95% CI) | AER | 30-Year Cumulative Incidence (95% CI) | No. | SIR (95% CI) | AER | 30-Year Cumulative Incidence (95% CI) | $P^*$ |
|----------------------|-----|-----------|-----|--------------|-----|--------------------------------------|-----|--------------|-----|--------------------------------------|------|
|                      | Male| < 35 Years Old |     |              |     |                                      |     |              |     |                                      |      |
| Cancer overall       | 183 | 3.68 to 4.92 | 47  | 13.9 (11.6 to 16.4) | 491 | 2.08 (1.91 to 2.28) | 111 | 20.4 (18.8 to 22.0) | <.001 |
| Colorectum           | 18  | 2.57 to 6.46 | 4   | 1.4 (0.7 to 2.3) | 55  | 1.73 (1.33 to 2.26) | 10  | 2.2 (1.6 to 2.8) | <.001 |
| Lung                 | 19  | 3.93 to 9.68 | 5   | 2.0 (1.1 to 3.3) | 76  | 3.20 (2.56 to 4.00) | 21  | 3.0 (2.3 to 3.6) | .02  |
| Breast               | 1   | 1.78 to 8.93 | 0.3 | 0.1 (0.0 to 0.6) | 2   | 4.58 (1.14 to 18.29) | 0.6 | 0.1 (0.0 to 0.3) | .44  |
| SCC (skin)           | 8   | 2.94 to 11.77| 2   | 0.3 (0.2 to 1.1) | 54  | 3.96 (3.03 to 5.18) | 17  | 2.0 (1.5 to 2.7) | .32  |
| Non-Hodgkin lymphoma | 33  | 11.28 to 22.32| 10  | 2.9 (1.9 to 4.2) | 56  | 6.93 (5.32 to 9.02) | 19  | 2.4 (1.8 to 3.1) | <.001 |
| Leukemia             | 19  | 7.75 to 19.05| 5   | 1.5 (0.8 to 2.3) | 36  | 6.57 (4.02 to 7.72) | 12  | 1.3 (0.9 to 1.8) | .01  |
|                      | Female| > 35 Years Old |     |              |     |                                      |     |              |     |                                      |      |
| Cancer overall       | 188 | 3.93 to 5.32 | 64  | 24.5 (21.0 to 28.2) | 259 | 1.73 (1.53 to 1.96) | 67  | 14.9 (13.3 to 16.6) | <.001 |
| Colorectum           | 4   | 0.49 to 3.48 | 0.4 | 0.6 (0.2 to 1.7) | 35  | 1.65 (1.19 to 2.30) | 8   | 2.1 (1.5 to 2.9) | .65  |
| Lung                 | 20  | 5.70 to 13.70| 34  | 13.8 (11.1 to 16.9) | 47  | 1.14 (0.85 to 1.51) | 3   | 3.3 (2.2 to 3.9) | <.001 |
| Breast               | 96  | 4.91 to 7.33 | 34  | 1.3 (0.3 to 1.9) | 33  | 4.87 (3.46 to 6.85) | 15  | 1.9 (1.3 to 2.7) | .29  |
| Non-Hodgkin lymphoma | 5   | 2.65 to 15.31| 2   | 0.1 (0.0 to 0.6) | 30  | 2.06 (1.47 to 2.85) | 15  | 1.6 (1.1 to 2.4) | .90  |
| Leukemia             | 21  | 2.96 to 13.04| 3   | 0.6 (0.2 to 1.2) | 15  | 4.51 (2.72 to 7.48) | 7   | 0.9 (0.5 to 1.4) | .05  |

Abbreviations: AER, absolute excess risk (No./10,000 person-years); HL, Hodgkin lymphoma; SCC, squamous cell carcinoma; SIR, standardized incidence ratio.

*Test of difference between SIRs.
†$P < .001$.
‡$P < .01$.
§$P < .05$.

Table 3. Risk of Second Cancer after Diagnosis of Hodgkin Lymphoma by Sex and Age at HL Diagnosis

© 2017 by American Society of Clinical Oncology.
This analysis provides further evidence that survivorship from HL is associated with a significant risk of a second cancer. Furthermore, we confirm the previous findings of a relationship between age at diagnosis and sex, and the risk of second cancers. Our analysis also shows that differences in patient management over successive decades have not led to a lessening of risk of second cancers in HL survivors, an observation consistent with recent data from the Netherlands. Possible reasons for this observation include the impact of screening or that the risk is maintained because of an interaction between less toxic chemotherapy and second cancer risk. For example, higher doses of alkylating agents, which are more likely to cause premature menopause, have been reported to reduce radiation-induced breast cancer risk. In addition, although patients diagnosed with HL are likely to have received lower doses of alkylating agents in recent years, the omission of radiotherapy from such treatment regimens is likely to have led to an increased proportion of all patients receiving alkylating agents. Finally, we cannot exclude entirely the possibility that the study periods we analyzed were too short or early to be able to demonstrate a difference.

In this study, HL survivors with a family history of colorectal, lung, or breast cancer showed an increased risk of concordant second cancers when compared with HL survivors without a family history. To our knowledge, this is the first population study to demonstrate site-specific second cancer risk after HL being influenced by family history. Our findings support the notion of familial determinants of second cancer risk being consistent with inherited genetic predisposition. Direct evidence for such a model is provided by the example of retinoblastoma, in which individuals with hereditary retinoblastoma have a much higher risk of radiotherapy-induced second malignancy compared with those with sporadic disease. Thus far, no similar high-impact mutation has been identified for HL, and sequencing of TP53, BRCA1, BRCA2, and ATM in HL survivors with a second malignancy has not substantiated a role for mutations in these genes as a cause of subsequent cancer risk. Polygenic susceptibility provides an alternative explanation for genetic susceptibility, whereby the elevated risk is enshrined in common genetic variants, which, in

Table 4. Risk of All Second Cancers and Site-Specific Cancers in Survivors of Hodgkin Lymphoma, by Family History

| Cancer Site | Relatives With Cancer | No. | SIR (95% CI) | No. | SIR (95% CI) | P* |
|-------------|-----------------------|-----|-------------|-----|-------------|----|
| All second cancer | 0 | 667 | 2.16 (2.00 to 2.33) | 454 | 2.83 (2.58 to 3.10) | < .001 |
| First-degree relative with cancer at any site | ≥ 1 | | | | | |
| Colorectum | 101 | 1.76 (1.45 to 2.14) | 11 | 3.71 (2.05 to 6.70) | .03 |
| Lung | 126 | 3.39 (2.85 to 4.03) | 12 | 11.24 (6.38 to 19.79) | < .001 |
| Breast (female) | 125 | 2.36 (1.98 to 2.81) | 18 | 4.36 (2.60 to 6.55) | .04 |
| Squamous cell carcinoma (skin) | 95 | 4.30 (3.52 to 5.26) | 5 | 10.85 (4.52 to 26.08) | .08 |
| Non-Hodgkin lymphoma | 121 | 7.83 (6.55 to 9.36) | 4 | 14.43 (5.41 to 38.43) | .27 |
| Leukemia | 77 | 6.37 (5.10 to 5.97) | 2 | 14.31 (3.58 to 57.21) | .32 |

Abbreviation: SIR, standardized incidence ratio.

*P values represent a test for trend.
isolation, exert small effects but act in concert to have a relatively profound impact. Such an assertion is supported by the recent findings that variation in FGFR2 and PRDM1 influences the risk of second cancer in HL survivors. For lung cancer, we were able to demonstrate a greater than additive interaction between family history of lung cancer and HL treatment, which may be the consequence of additional shared nongenetic risk factors, most probably a propensity to smoke. This interaction is of significant consequence of additional shared nongenetic risk factors, most probably a propensity to smoke. This interaction is of significant importance because it may explain, in part, why no significant change in second lung cancer has been observed despite modifications in treatment regimens. The number of cases of breast and colorectal cancer did not permit the rejection of any interaction model.

Survival of patients with HL after diagnosis of a second cancer was not significantly worse in those with an affected FDR. Moreover, noninferiority of survival in individuals with a family history of cancer has been described in colorectal, breast, and prostate cancer. Although it remains to be established, reasons for this may include increased cancer surveillance, resulting in presentation at earlier stages of disease, improved health-related behavior, or differences in tumor biology and response to therapy.

Our study has major strengths. First, we have avoided ascertainment bias in patient selection because our cohort analysis was based on the Swedish population, for which there is near complete case registration with long-term follow-up. Second, the Swedish Family-Cancer Project Database includes a large number of individuals linked to family members, and this has allowed us to uniquely study the influence of family history on cancer risk. We do acknowledge, however, that a limitation of our study is the reliance on year of treatment as an effective surrogate for type of treatment and that we did not have the opportunity to incorporate information on risk factors such as smoking. However, most of the familial risk of lung cancer is a result of a predisposition to smoke. Hence, by performing an interactive analysis, we addressed this area.

Despite these caveats, our findings further substantiate the significant cancer risks associated with survivorship from HL and that these are modified by a family history of cancer. In addition, our findings are of importance in a primary health care setting where many surviving patients with HL are treated (for other symptoms and diseases) after the first 5 years of follow-up. Long-term understanding of the biologic basis of these associations offers the prospect of personalizing therapy in HL. However, such information has current value clinically, when planning risk-adapted therapy for patients with HL. Furthermore, our findings with respect to lung cancer emphasize the importance of instigating programs to reduce smoking in patients with HL. Finally, as well as offering breast cancer screening to women who have received supradiaphragmatic radiotherapy, obtaining family history information has a place in informing the long-term follow-up screening of all patients with HL.

Table 5. Interaction Between Risk of Second Cancer in Survivors of Hodgkin Lymphoma and Family History of Concordant Cancer in the Swedish Population

| Cancer Site | Risk in Population With an FDR With Concordant Cancer, SIR (95% CI) | Risk in HL Survivors With an FDR With Cancer, SIR (95% CI) | Risk in HL Survivors With an FDR With Cancer, SIR (95% CI) | Type of Interaction | Additive | Multiplicative |
|-------------|---------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|------------------|----------|---------------|
| Colorectum  | 1.87 (1.82 to 1.93)                                            | 1.85 (1.54 to 2.23)                              | 3.71 (2.05 to 6.70)                               | ICR (95% CI)      | 0.99     | 0.98 to 4.09  |
| Lung        | 2.12 (2.03 to 2.21)                                            | 3.61 (3.05 to 4.36)                              | 11.24 (6.38 to 19.79)                            | P                | 0.76     | 1.08 (0.50 to 2.10) |
| Breast      | 1.85 (1.81 to 1.88)                                            | 2.52 (2.15 to 2.97)                              | 4.36 (2.60 to 6.55)                               | MII (95% CI)      | 0.99     | 0.71 to 3.68  |

Abbreviations: ICR, interaction contrast ratio; HL, Hodgkin lymphoma; FDR, first-degree relative; MII, multiplicative interaction index; P, probability ICR > 0 and MII > 1; SIR, standardized incidence ratio.

*Significantly worse in those with an affected FDR.

REFERENCES
1. Canellos GP, Rosenberg SA, Friedberg J., et al: Treatment of Hodgkin lymphoma: A 50-year perspective. J Clin Oncol 32:163-168, 2014
2. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al: Second cancer risk following Hodgkin’s disease: A 20-year follow-up study. J Clin Oncol 12:312-325, 1994
3. Swerdlow AJ, Barber JA, Hudson GV, et al: Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment. J Clin Oncol 18:498-509, 2000
4. van Leeuwen FE, Klokman WJ, Veer MB, et al: Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 18:487-497, 2000
5. Ng AK, Bernardo MV, Weller E, et al: Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors. Blood 100:1989-1996, 2002
6. Dores GM, Metayer C, Curtis RE, et al: Second malignant neoplasms among long-term survivors of Hodgkin’s disease: A population-based evaluation over 25 years. J Clin Oncol 20:3484-3494, 2002
7. Bhata S, Yasa Y, Robison LL, et al: High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’s disease: Report from the Late Effects Study Group. J Clin Oncol 21: 4388-4394, 2003
Sud et al

8. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al: Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109:1878-1886, 2007
9. Hodgson DC, Gilbert ES, Dores GM, et al: Long-term solid cancer risk among 5-year survivors of Hodgkin’s lymphoma. J Clin Oncol 25:1498-1507, 2007
10. Swerdlow AJ, Higgins CD, Smith P, et al: Second cancer risk after chemotherapy for Hodgkin’s lymphoma: A collaborative British cohort study. J Clin Oncol 29:4096-4104, 2011
11. van Eggermond AM, Schaapveld M, Lugtenburg PJ, et al: Risk of multiple primary malignancies following treatment of Hodgkin lymphoma. Blood 124:319-327, quiz 466, 2014
12. Schaapveld M, Aleman BM, van Eggermond AM, et al: Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med 373:2499-2511, 2015
13. Kreissl S, Mueller H, Goergen H, et al: Cancer-related fatigue in patients with and survivors of Hodgkin’s lymphoma: A longitudinal study of the German Hodgkin Study Group. Lancet Oncol 17:1453-1462, 2016
14. De Bruin ML, Sporidian J, van’t Veer MB, et al: Breast cancer risk in female survivors of Hodgkin’s lymphoma: Lower risk after smaller radiation volumes. J Clin Oncol 27:4239-4246, 2009
15. van Leeuwen FE, Klokman WJ, Stovall M, et al: Roles of radiotherapy and smoking in lung cancer following Hodgkin’s disease. J Natl Cancer Inst 87:1530-1537, 1995
16. Nichols KE, Levitz S, Shannon KE, et al: Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin’s disease. J Clin Oncol 17:1259, 1999
17. Meadows AT, Strong LC, Li FP, et al: Bone sarcoma as a second malignant neoplasm in children: Influence of radiation and genetic predisposition for the Late Effects Study Group. Cancer 46:2603-2606, 1980
18. Andersson A, Enblad G, Tavelin B, et al: Family history of cancer as a risk factor for second malignancies after Hodgkin’s lymphoma. Br J Cancer 98:1001-1005, 2008
19. Hemminki K, Li X, Pfla K, et al: The nation-wide Swedish Familial-Cancer Database—updated structure and familial rates. Acta Oncol 40:772-777, 2001
20. Barlov L, Westergren K, Holmberg L, et al: The completeness of the Swedish Cancer Register: A sample survey for year 1998. Acta Oncol 48:27-33, 2009
21. Lei M, Reilly M, Czene K: Evaluation of bias in familial risk estimates: A study of common cancers using Swedish population-based registers. J Natl Cancer Inst 100:1318-1325, 2008
22. Hemminki K, Ji J, Brandt A, et al: The Swedish Family-Cancer Database 2009: Prospects for histology-specific and immigrant studies. Int J Cancer 126:2259-2267, 2010
23. Thellinenberg C, Melin B, Tavelin B, et al: Second primary cancers in men with prostate cancer: An increased risk of male breast cancer. J Urol 169:1345-1348, 2003
24. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 94:496-509, 1999
25. Zhang H, Bernejo JL, Sundquist J, et al: Prostate cancer as a first and second cancer: Effect of family history. Br J Cancer 101:935-939, 2009
26. Ederer F, Axtell LM, Cutler SJ: The relative survival rate: A statistical methodology. Nati Cancer Inst Monogr 6:101-121, 1961
27. Pohar M, Stare J: Relative survival analysis in R. Comput Methods Programs Biomed 81:272-278, 2006
28. R Development Core Team: R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. 2015
29. Sjöberg J, Halturh C, Kristinsson SY, et al: Progress in Hodgkin lymphoma: A population-based study on patients diagnosed in Sweden from 1973-2009. Blood 119:990-996, 2012
30. Englund A, Hopstadius C, Enblad G, et al: Hodgkin lymphoma—a survey of children and adolescents treated in Sweden 1985-2009. Acta Oncol 54:41-48, 2015
31. Travi LS, Hill DA, Dores GM, et al: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290:465-475, 2003
32. Draper DJ, Sanders BM, Kingston JE: Second primary neoplasms in patients with retinoblastoma. Br J Cancer 53:661-671, 1986
33. Marees T, Moll AC, Imhof SM, et al: Risk of second malignancies in survivors of retinoblastoma: More than 40 years of follow-up. J Natl Cancer Inst 100:1771-1779, 2008
34. Nichols KE, Heath JA, Friedman D, et al: TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin’s disease with second primary neoplasms. J Clin Oncol 21:4505-4509, 2003
35. Ma YP, van Leeuwen FE, Cooke R, et al: FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma. Blood 119:1029-1031, 2012
36. Best T, Li D, Skol AD, et al: Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin’s lymphoma. Nat Med 17:941-943, 2011
37. Thalib L, Wedin S, Granath F, et al: Breast cancer prognosis in relation to family history of breast and ovarian cancer. Br J Cancer 90:1378-1381, 2004
38. Morris EJ, Penegar S, Whitehouse LE, et al: A retrospective observational study of the relationship between family history and survival from colorectal cancer. Br J Cancer 108:1502-1507, 2013
39. Lee, M, Reilly, M, Lindström, LS, et al: Differences in survival for patients with familial and sporadic cancer. Int J Cancer, 140:581-590, 2017
40. Wallner LP, Sarma AV, Lieber MM, et al: Psychosocial factors associated with an increased frequency of prostate cancer screening in men ages 40 to 79 years: The Olmsted County study. Cancer Epidemiol Biomarkers Prev 17:3986-3992, 2008
41. Williams KA, Reiter P, Mabiso A, et al: Family history of cancer predicts Papanicolaou screening behavior for African American and white women. Cancer 115:179-189, 2009
42. Tracy KA, Quillin JM, Wilson DB, et al: The impact of family history of breast cancer and cancer death on women’s mammography practices and beliefs. Genet Med 10:621-625, 2008
43. Howell SJ, Searle C, Goode V, et al: The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. Br J Cancer 101:582-588, 2009
44. Ng AK: Current survivorship recommendations for patients with Hodgkin lymphoma: Focus on late effects. Blood 124:3373-3379, 2014

Affiliations

Amit Sud and Richard S. Houlston, The Institute of Cancer Research, London, United Kingdom; Hauke Thomsen and Kari Hemminki, German Cancer Research Centre, Heidelberg, Germany; and Kristina Sundquist and Kari Hemminki, Centre for Primary Health Care Research, Lund University, Malmö, Sweden.

Support

Supported by the German Cancer Aid, the Swedish Research Council, FORTE, and an ALF project grant, Region Skåne/Lund University, Sweden, and by a clinical fellowship from Cancer Research UK (A.S.).
# Authors' Disclosures of Potential Conflicts of Interest

## Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/jco/site/ifc](http://ascopubs.org/jco/site/ifc).

| Author            | Relationship to Disclose                  |
|-------------------|-------------------------------------------|
| Amit Sud          | No relationship to disclose               |
| Hauke Thomsen     | No relationship to disclose               |
| Kristina Sundquist| No relationship to disclose               |
| Richard S. Houlton| No relationship to disclose               |
| Kari Hemminki     | No relationship to disclose               |